Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.

Yong-Yu Mei You-Ming Chen Yuan-Kai Wu Xiao-Hong Zhang Wen-Xiong Xu

Published in: Canadian journal of gastroenterology & hepatology (2020)

SOF-based DAAs regimen can achieve ideal SVR12 for Chinese patients with both GT3a and GT6a HCV infection. The tolerance and safety of SOF-based DAAs regimen are good.

Keyphrases

hepatitis c virus infection
hepatitis c virus
human immunodeficiency virus
smoking cessation